AU2006209547C1 - Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor - Google Patents

Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor Download PDF

Info

Publication number
AU2006209547C1
AU2006209547C1 AU2006209547A AU2006209547A AU2006209547C1 AU 2006209547 C1 AU2006209547 C1 AU 2006209547C1 AU 2006209547 A AU2006209547 A AU 2006209547A AU 2006209547 A AU2006209547 A AU 2006209547A AU 2006209547 C1 AU2006209547 C1 AU 2006209547C1
Authority
AU
Australia
Prior art keywords
cancer
ftd
day
dose
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2006209547A
Other languages
English (en)
Other versions
AU2006209547B2 (en
AU2006209547A1 (en
Inventor
Tomohiro Emura
Akira Mita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006209547(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2006209547A1 publication Critical patent/AU2006209547A1/en
Publication of AU2006209547B2 publication Critical patent/AU2006209547B2/en
Application granted granted Critical
Publication of AU2006209547C1 publication Critical patent/AU2006209547C1/en
Assigned to LES LABORATORIES SERVIER reassignment LES LABORATORIES SERVIER Request for Assignment Assignors: TAIHO PHARMACEUTICAL CO., LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006209547A 2005-01-26 2006-01-25 Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor Expired AU2006209547C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/042,059 2005-01-26
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
JP2005-165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (3)

Publication Number Publication Date
AU2006209547A1 AU2006209547A1 (en) 2006-08-03
AU2006209547B2 AU2006209547B2 (en) 2011-05-26
AU2006209547C1 true AU2006209547C1 (en) 2022-04-07

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006209547A Expired AU2006209547C1 (en) 2005-01-26 2006-01-25 Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor

Country Status (20)

Country Link
EP (1) EP1849470B2 (OSRAM)
JP (1) JP5576591B2 (OSRAM)
KR (1) KR101468216B1 (OSRAM)
AU (1) AU2006209547C1 (OSRAM)
BE (1) BE2017C028I2 (OSRAM)
CA (1) CA2594713A1 (OSRAM)
CY (2) CY1119393T1 (OSRAM)
DK (1) DK1849470T4 (OSRAM)
ES (1) ES2630002T5 (OSRAM)
FI (1) FI1849470T4 (OSRAM)
FR (1) FR17C1028I2 (OSRAM)
HU (2) HUE033306T2 (OSRAM)
LT (2) LT1849470T (OSRAM)
LU (1) LUC00036I2 (OSRAM)
NL (1) NL300889I2 (OSRAM)
PL (1) PL1849470T5 (OSRAM)
PT (1) PT1849470T (OSRAM)
SI (1) SI1849470T2 (OSRAM)
TW (1) TWI362265B (OSRAM)
WO (1) WO2006080327A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1849470B2 (en) 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
WO2008132443A1 (en) 2007-04-25 2008-11-06 Cyclacel Limited Use of sapacitabine to treat proliferative disease
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
AU2009248037A1 (en) * 2008-05-15 2009-11-19 Katholieke Universiteit Leuven, K.U. Leuven R&D Anti-cancer combination therapy
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
EP2746404B1 (en) 2011-08-16 2017-12-06 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
SG11201406550QA (en) * 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
TWI615145B (zh) 2013-03-27 2018-02-21 Taiho Pharmaceutical Co Ltd 含伊立替康鹽酸鹽水合物之抗腫瘤劑
AU2014245147B2 (en) 2013-03-27 2017-08-31 Les Laboratoires Servier Antitumor agent including low-dose irinotecan hydrochloride hydrate
US20160082032A1 (en) 2013-05-17 2016-03-24 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
UA121538C2 (uk) 2013-09-06 2020-06-25 Тайхо Фармасьютікал Ко., Лтд. Спосіб лікування злоякісного новоутворення
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
UA125119C2 (uk) * 2016-01-08 2022-01-12 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний засіб, що містить імуномодулятор і підсилювач протипухлинного ефекту
UA123403C2 (uk) 2016-02-05 2021-03-31 Тайхо Фармасьютікал Ко., Лтд. Спосіб лікування хворих на рак з тяжкою нирковою недостатністю
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2026019875A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255314B1 (en) * 1996-09-24 2001-07-03 Taiho Charmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
EP1849470B2 (en) 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
US6294535B1 (en) * 1995-03-29 2001-09-25 Taiho Pharmaceutical Co., Ltd. Uracil derivatives and antitumor effect potentiator and antitumor agent containing the same

Also Published As

Publication number Publication date
AU2006209547B2 (en) 2011-05-26
CA2594713A1 (en) 2006-08-03
PL1849470T5 (pl) 2024-06-10
PT1849470T (pt) 2017-09-22
LTPA2017024I1 (lt) 2017-08-10
SI1849470T1 (sl) 2017-10-30
BE2017C028I2 (OSRAM) 2025-09-10
RU2007132181A (ru) 2009-03-10
LUC00036I1 (OSRAM) 2017-10-02
CY2017029I1 (el) 2018-02-14
KR20070104559A (ko) 2007-10-26
SI1849470T2 (sl) 2024-05-31
HUS1700032I1 (hu) 2017-09-28
PL1849470T3 (pl) 2017-11-30
JP5576591B2 (ja) 2014-08-20
FR17C1028I1 (OSRAM) 2017-09-29
EP1849470A1 (en) 2007-10-31
LUC00036I2 (OSRAM) 2017-12-01
LT1849470T (lt) 2017-07-25
CY1119393T1 (el) 2018-02-14
TW200637562A (en) 2006-11-01
FI1849470T4 (fi) 2024-03-22
JPWO2006080327A1 (ja) 2008-06-19
EP1849470B2 (en) 2024-03-20
DK1849470T4 (en) 2024-04-02
ES2630002T5 (es) 2024-09-19
WO2006080327A1 (ja) 2006-08-03
FR17C1028I2 (fr) 2018-11-02
HUE033306T2 (hu) 2017-11-28
NL300889I1 (nl) 2017-08-14
EP1849470B1 (en) 2017-06-21
CY2017029I2 (el) 2018-02-14
EP1849470A4 (en) 2010-12-08
LTC1849470I2 (lt) 2019-10-25
AU2006209547A1 (en) 2006-08-03
NL300889I2 (nl) 2018-01-16
RU2394581C2 (ru) 2010-07-20
TWI362265B (en) 2012-04-21
ES2630002T3 (es) 2017-08-17
DK1849470T3 (en) 2017-08-14
KR101468216B1 (ko) 2014-12-03

Similar Documents

Publication Publication Date Title
AU2006209547B2 (en) Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
US20090281105A1 (en) Radiotherapy enhancer
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
TWI401085B (zh) Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
JPWO2012105486A1 (ja) １日１回隔日投与を特徴とするテガフール含有組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 DEC 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 03 DEC 2021

PC Assignment registered

Owner name: LES LABORATORIES SERVIER

Free format text: FORMER OWNER(S): TAIHO PHARMACEUTICAL CO., LTD.

TH Corrigenda

Free format text: IN VOL 59 , NO 51 , PAGE(S) 7206 UNDER THE HEADING ASSIGNMENTS REGISTERED CORRECT THE NAME OF THE ASSIGNEE TO READ: LES LABORATOIRES SERVIER.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired